×
SAHMRI. Inspired research, better health.
Precision Medicine
12 December, 2019

Major breakthrough for leukaemia treatment

Precision Medicine

An international clinical trial involving Adelaide researchers has demonstrated the safety and efficacy of a next-generation treatment for people with chronic myeloid leukaemia (CML).

The study’s lead author, Professor Tim Hughes, says successful development and testing of the new kinase inhibitor called asciminib is the biggest breakthrough in CML treatment this century.

The development of the original tyrosine kinase inhibitor (TKI) called imatinib in the 1990s changed CML from a death sentence to a disease that in many patients could be managed until they lived to a ripe old age,” Professor Hughes said.

“But while imatinib and subsequent TKIs have been very effective at improving survival, they frequently cause serious side-effects.”

TKIs that are currently approved for use are not well targeted, attacking leukaemic cells but also damaging healthy cells. Professor Hughes, a Cancer Council SA Beat Cancer Professor, says asciminib selectively blocks the mutant kinase present in the leukaemic cells.

“This trial of 150 patients showed asciminib is highly effective, even in patients who’d failed to respond to several other TKIs,” Professor Hughes said.

“Equally as important, it’s well tolerated by patients and appears to have significantly less longterm ill-effects compared to current treatments.”

The results of this clinical trial were published today in the esteemed New England Journal of Medicine.

CML is a blood cancer that causes bone marrow to produce too many white blood cells. This excess of mutant white blood cells interferes with normal blood cell production. TKIs slow or stop this excess production of white blood cells.

More than 4,000 Australians are living with CML currently however the increasingly high survival rate brought about by TKI treatment means the disease is estimated to be the most common form of leukaemia by 2040.

You can't miss us

North Terrace
Adelaide 5000
South Australia

Postal address

PO Box 11060
Adelaide 5001
South Australia

Connect

Key partners

Founding memberFounding memberFounding memberFounding memberCapital supportMajor funderResearch partnerResearch partner

SAHMRI is located on the traditional lands of the Kaurna people.

The SAHMRI community acknowledges and pays respect to the Kaurna people as the traditional custodians of the Adelaide region. We also acknowledge the deep feelings of attachment and the relationship of the Kaurna people to their country. We pay our respects to the Kaurna peoples' ancestors and the living Kaurna people today.